LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Wayne C....
TULSA, Okla., Sept. 22, 2021 /PRNewswire/ -- ONEOK, Inc. (NYSE: OKE) today announced a companywide greenhouse gas (GHG) emission reduction target. The company...
Boston Scientific Corp. has agreed to acquire Devoro Medical Inc. in a deal expected to close this year. Boston Scientific previously held a 16% equity stake in Devoro Medical and now agrees to acquire the remaining 84% stake for $269M. Boston Scientific also agrees to pay up to $67M more if Devoro Medical clears certain regulatory and clinical milestones.
Devoro Medical is the developer of the WOLF Thrombectomy® Platform–a technology platform that “targets and rapidly captures blood clots using finger-link prongs that retrieve and remove thrombi in the arterial and venous systems.”
“The addition of the WOLF platform advances our efforts to ensure physicians have the right tools to improve procedural efficiencies,” said Jeff Mirviss, executive vice president and president, Peripheral Interventions at Boston Scientific. “Clot management remains a core focus of our business, and upon commercialization, this highly differentiated technology will complement and expand our offerings to a full suite of interventional strategies for thromboemboli, which also includes the EkoSonic™ Endovascular System (EKOS) and the AngioJet™ Thrombectomy System.”
Boston Scientific plans to accelerate development of the WOLF platform following its acquisition of Devoro Medical, according to Michael R. Jaff, D.O., its Chief Medical Officer and Vice President of Clinical Affairs, Technology and Innovation, Peripheral Interventions.
This deal is the latest in a series of acquisitions this year by Boston Scientific. In January, Boston Scientific agreed to acquire cardiac wearables company Preventice Solutions for $925M. In March, Boston Scientific agreed to acquire the global surgical business of Lumenis LTD for $1.07B. And, in June, Boston Scientific agreed to acquire cardiac ablation device maker Farapulse for $295M.
MicroVentures is a broker-dealer that raises capital under the various crowdfunding exemptions including Reg CF+, Reg D, and Reg A+. An early entrant...
The ongoing economic crisis in China has threatened the crypto space. With the increase in FUDs BTC price dropped by 11% within 24 hours. Analysts and investors have considered this dip as a buying opportunity. Well, Glassnode, a crypto metric platform revealed data that shown illiquid supply hit new ATH reaching 14.43 million BTC. This …
Posted on Sep 22, 2021 Companies Anticipate Investigations into Three Key Areas: Business Conduct and Treatment of Customers, Sustainability/ESG Practices, and Relationship with...
THE WOODLANDS, Texas, Sept. 22, 2021 /PRNewswire/ -- Huntsman Corporation (NYSE: HUN) announced today that it was implementing a natural gas surcharge of...
Blockchain technology provider Polymath announced today that Polymesh, an institutional-grade permissioned blockchain built specifically for regulated assets, will be launched by the Polymesh...